National Research Network 2011 Benchmark Report
|
|
|
- Harvey Richards
- 6 years ago
- Views:
Transcription
1 National Research Network 211 Benchmark Report The National Research Network 211 Benchmark Report pulls together real world performance data from hospitals, universities and government agencies across the National Research Network. It is provided as a service to the human subject research community to assist organizations as they benchmark internal performance. The 211 Benchmark Report includes data sampled from April 21 - March 211. IRBNet 211
2 Background Na$onal Research Network 211 Benchmark Report The Na'onal Research Network 211 Benchmark Report pulls together real world performance data from hospitals, universi'es and government agencies across the Na'onal Research Network (NRN). It is provided as a service to the human subject research community to assist organiza'ons as they benchmark internal performance. The 211 Benchmark Report includes data from 69 randomly selected ins'tu'ons ac've on the Na'onal Research Network, sampled from April 21 - March 211. Anonymous selec'on was based upon tenure, volume of ac'vity, ins'tu'onal profile, completeness of data and other factors.
3 About the Data: Ins$tu$onal Research Profile 6% of analyzed research is biomedical in nature; hospitals and universi$es report varied research focus. Overall Profile: 6% Biomedical social / behavioral 4% Hospital Profile: 89% Biomedical social / behavioral 11% University Profile: 69% Social/Behavioral biomedical: non-oncology 12% biomedical: non-oncology 24% biomedical: oncology 36% biomedical: non-oncology 35% biomedical: oncology 54% biomedical: oncology 19% social / behavioral 69% N = 69 N = 44 N = 25 National Research Network 211 Benchmark Report 211
4 Days to and Approval by Type 32% of total $me to first approval for convened review projects is due to inves$gator errors, omissions and response to commimee decisions (38% for expedited reviews). Days to and First Approval Convened : Submission to Convened : Submission to Initial Approval National Research Network 211 Benchmark Report 14.7 Expedited : Submission to 36.1 Expedited : Submission to Initial Approval 13.7 Exempt : Submission to Determination Includes multiple submissions when required to obtain initial approval. Administrative and Expedited / Convened Response to Committee Decisions Errors / Omissions 2 Errors / Omissions and investigator responses less than.1 211
5 Convened Total convened review $mes are similar across categories; universi$es issue post- review lemers in 4 days. 4 Convened Time to Letter After Decision to Decision Administrative Pre Average Hospital University Biomedical Social / Behavioral National Research Network 211 Benchmark Report Errors / Omissions 211
6 Days to First Approval by Type Hospitals approve new studies via convened review at a faster rate than the na$onal average. Days to First Approval 7 Convened 6 5 Administrative Pre- and Convened Response to Committee Decisions Errors / Omissions Average Hospital University Biomedical Social / Behavioral National Research Network 211 Benchmark Report 211
7 Number of Submissions to Obtain Ini$al Approval (Convened ) 18% of studies approved by convened review required three or more submissions to obtain ini$al IRB approval. Number of Submissions to Obtain Initial Approval number of submissions % Convened 82% National Research Network 211 Benchmark Report % 99% 1% submissions 1% 9% 8% 7% 6% 5% 4% 3% 2% 1% % % approved
8 Expedited On average, 23% of the $me to complete expedited review is consumed by inves$gator rework of errors and omissions. 25 Expedited Average Hospital University Biomedical Social / Behavioral Time to Letter After Decision Administrative/ Expedited Rework due to Errors / Omissions National Research Network 211 Benchmark Report 211
9 Expedited NRN Members complete expedited reviews in less than 15 days on average. 25 Expedited Expedited 5 Average New Continuing Other National Research Network 211 Benchmark Report 211
10 Expedited Errors and omissions average more than 5 days for new and con$nuing reviews. 25 Expedited New and Continuing Time to Letter After Decision Administrative Pre- and Expedited Rework due to Errors / Omissions Average Hospital University Biomedical Social / Behavioral National Research Network 211 Benchmark Report 211
11 Days to First Approval by Type Hospitals approve new studies via expedited review at a faster rate than the na$onal average. Days to First Approval Expedited Administrative Pre- and Expedited Response to Expedited Decisions Errors / Omissions Average Hospital University Biomedical Social / Behavioral National Research Network 211 Benchmark Report 211
12 Staffing and Workload NRN members efficiently manage large protocol workloads, with an average of only 3 Staff FTEs. Staffing and Protocol Workload Average Number of Protocols Average Number of IRB Staff (FTE) Protocols per FTE Ins$tu$ons with 1-5 Ac$ve Protocols (Expedited, Convened) Ins$tu$ons with 51-1 Ac$ve Protocols (Expedited, Convened) National Research Network 211 Benchmark Report 211
13 If you would like to automa$cally receive future copies of Na$onal Research Network Benchmark Reports you may submit your request to
National Research Network 2012 Benchmark Report
National Research Network 212 Benchmark Report The National Research Network 212 Benchmark Report pulls together real world performance data from hospitals, universities and government agencies across
2013 Metrics on Human Research Protection Program Performance
2013 Metrics on Human Research Protection Program Performance Updated August 1, 2014 About the Metrics Improving the quality of human research protection programs (HRPP) is a top priority of AAHRPP. Effective
Clinical Trial Billing Compliance at UAB
Clinical Trial Billing Compliance at UAB Carolyn P. Whitmire, MBA, CHRC Director, Research Implementa?on Co- Administra?ve Director, Clinical Trials Office UAB Infrastructure Campus and Health System are
The Role of the IRB in Clinical Trials: What Patients and Families Need to Know. Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation
The Role of the IRB in Clinical Trials: What Patients and Families Need to Know Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation 1 CAC2 Values v Put the children and their families first in
I R B N E T I N T E R V I E W S E R I E S
Paul Garfinkel MSH, CIP Paul Garfinkel is the Director of the Office of Human Subject Protection for Nemours, as well the Institutional Official. He has held this position since 2004, and has 32 years
Human Research Participant Protection Program Institutional Review Board (IRB)
Human Research Participant Protection Program Institutional Review Board (IRB) Procedure 1: Determining whether a research activity needs IRB review and approval 1. Subject All research activities that
Human Subjects Research. Kelley A. O Donoghue, MPH, CIP Director Office for Human Subject Protection
Human Subjects Research Kelley A. O Donoghue, MPH, CIP Director Office for Human Subject Protection kelley_odonoghue@urmc.rochester.edu Belmont Report Respect for Persons (Autonomy) Informed Consent Protect
Final Outcome of ASW Symposium
Symposium on the ASEAN Single Window and National Single Windows Borobudur Hotel, Jakarta, Indonesia 18 September 2012 Summary of Session 5 Final Outcome of ASW Symposium 1 ü The current ASW architecture
University of the Virgin Islands Institutional Review Board (IRB) IRB Basics for Social Science Senior Seminar (STT/STX)
University of the Virgin Islands Institutional Review Board (IRB) IRB Basics for Social Science Senior Seminar (STT/STX) Ethics and Human Subject Protections Presented by: Olusola Ewulo, M.S. Director,
SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES
This policy applies to the following entity(s): Children s Hospital of Wisconsin Children s Hospital and Health System, Inc. Administrative Policy and Procedure Children s Research Institute SUBJECT: INSTITUTIONAL
Use of IRB Quality Metrics for Performance Assurance of the Ethics Committee
Use of IRB Quality Metrics for Performance Assurance of the Ethics Committee Pornpimon Adams FTM-EC Secretary Faculty of Tropical Medicine, Mahidol University Background Ethics Committee Faculty of Tropical
Human Subjects/IRB Compliance. Sue Flynn Human Subject Compliance Manager
Human Subjects/IRB Compliance Sue Flynn Human Subject Compliance Manager Your Resources at the Broad Sue Flynn, Human Subjects Compliance Manager sflynn@broadinstitute.org or 714-7221 Jackie Murphy, Human
Research Compliance Committees
Research Compliance Committees Ephy Khaemba, International Livestock Research Institute ILRI. Laboratory Management & Equipment Opera5ons Workshop. 1 Course Outline Structure of Regulatory Environment
Investigator Manual. Human Subjects Protection Program
Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the
Troubleshooting Informed Consent. Sandra Meadows, MPH, CIP Office of Responsible Research Practices June 26, 2018
Troubleshooting Informed Consent Sandra Meadows, MPH, CIP June 26, 2018 2 Session Objectives Identify common submission screening questions Examine IRB-required modifications related to the consent process
Outline of Discussion
This final rule is intended to better protect human subjects involved in research, while facilitating valuable research and reducing burden, delay, and ambiguity for investigators. These revisions are
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure
Tip Sheet 17: Review of Research by the Expedited Procedure
Tip Sheet 17: Review of Research by the Expedited Procedure Related Accreditation Elements: II.2.E. Policies and procedures should describe review using the expedited procedure, when an expedited procedure
KPIs and Assessment: Developing Measures to Achieve Goals and Support Accountability
KPIs and Assessment: Developing Measures to Achieve Goals and Support Accountability Canadian Career Development Summit Kempenfelt Conference Centre April 12, 2017 Jan Basso Experiential Learning & Career
Human Subjects Research: IRB Resources
Research Compliance Office Human Subjects Research: IRB Resources Kristin B. Frazier HRPP Educational Specialist IRB Resources June 4, 2008 Topics Stanford Institutional Review Boards (IRB) Charge of IRB
The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement
Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption
H-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS
H-20 Page 1 of 5 Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS PURPOSE: To describe the requirements for McLeod Health IRB review of Humanitarian Use Devices (HUD).
Iden'ty and Access Management Governance
Iden'ty and Access Management Governance Real world prac'ces that work in Higher Educa'on Roopa Chowbey Manager, Iden'ty management 1 Agenda Background Iden'ty and Access Management (IAM) program at George
Protocol Submission Form
Protocol Submission Form 1. Administrative Information Name of Submitting Party: Street: Province/State: Postal/Zip Code: Phone: ( ) E-mail Address: Fax: ( ) Other: ( ) Date: 2. General Study Information
Defining research compliance Protocol review committees Conflicts of interest Export Controls
Defining research compliance Protocol review committees Conflicts of interest Export Controls What is Research Compliance? Conformance with Federal, State, and Local Regulations and University Policies
Strategic Plan
2016 2020 Strategic Plan Mission NJVOAD s mission is to bring together New Jersey organiza9ons ac9ve in disaster assistance, and to foster coopera9on and coordina9on in preparedness, response, and recovery
Beyond Auditing and Monitoring and Towards Quality Improvement
Beyond Auditing and Monitoring and Towards Quality Improvement HCCA CI 2019 John Baumann, PhD. Associate Vice President for Research Compliance Office of Research Compliance Vice President for Research
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual Cindy Gates IRB Administration What is the purpose of the INVESTIGATOR MANUAL? The manual is designed
The Institutional Review Board (IRB) Manual
The Institutional Review Board (IRB) Manual Investigational Devices Policy Research that involves the use of investigational devices must conform to Food and Drug Administration (FDA) and Department of
11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
1 of 5 11/6/2014 3:08 PM
1 of 5 11/6/2014 3:08 PM : Thursday, November 6, 2014 1:07:42 PM : NU SF: Basic Information 1. * Title of study: Biomedical Research Study 2. * Short title: Biomedical Study 3. * Brief description: This
Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form
Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form A. Demographic Information Date of Submission: Reason for Submission: New Project Response to Comments Reconsideration Disapproval
What to Measure and How to Measure it Let s Talk Metrics!
What to Measure and How to Measure it Let s Talk Metrics! Sarah A. White, MPH, CIP Director, Quality Improvement Program Partners Healthcare swhite12@partners.org You see a lot. What is important to share?
11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
Expert Conference on Revision of Declara?on of Helsinki Tokyo, Japan. On March 1, 2013 Professor Somkiat Wa/anasirichaigoon, MD, FRCST
Expert Conference on Revision of Declara?on of Helsinki Tokyo, Japan. On March 1, 2013 Professor Somkiat Wa/anasirichaigoon, MD, FRCST Chairman, Medical Educa?on Sec?on, Medical Associa?on of Thailand
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS INSTITUTIONAL REVIEW BOARD. Emergency Use of an Investigational Drug, Biologic or Device
Emergency Use of an Investigational Drug, Biologic or Device Introduction The emergency use provision in the FDA regulations (21 CFR 56.102d) is an exemption from prior review and approval by the IRB for
1 GENERAL INFORMATION FOR ALL IRB MEMBERS FOR CONVENED MEETINGS Information for Other Business items Educational Materials
HRP-301 8/15/2017 1 of 5 The purpose of this worksheet is to provide support for IRB staff who prepare review materials for convened IRB meetings or prepare materials for Non-Committee Review. This worksheet
PHS Human Subjects and Clinical Trials Information
PHS Human Subjects and Clinical Trials Information OMB Number: 925-1 Expiration Date: 3/31/22 Please complete the human subjects section of the Research & Related Other Project Information form prior to
Landscape Analysis of CRISPR-Cas9. An analysis of patent publica1ons and literature in the CRISPR-Cas9 technology space
Landscape Analysis of CRISPR-Cas9 An analysis of patent publica1ons and literature in the CRISPR-Cas9 technology space 2 Objec:ve and Scope This study focuses on the nature of patent and non-patent literature
8 Most Significant Proposed Changes to the Common Rule. Susan L. Rose Office for the Protection of Research Subjects (OPRS)
8 Most Significant Proposed Changes to the Common Rule Susan L. Rose Office for the Protection of Research Subjects (OPRS) Overview 1. Informed Consent 2. Use of Biospecimens 3. Activities Excluded from
Requirements for Humanitarian Use Device (HUD)
Requirements for Humanitarian Use Device (HUD) 1. Definition of Humanitarian Use Device - The definition of a HUD is a device that is intended to benefit patients in the treatment and diagnosis of diseases
Can You S)ll Be an Individual? Brian Kahan, D.O. FAAPMR, DAOCPMR, DABIPP The Kahan Center for Pain Management
Can You S)ll Be an Individual? Brian Kahan, D.O. FAAPMR, DAOCPMR, DABIPP The Kahan Center for Pain Management www.thekahancenter.com Learning Objec)ves Developing survival strategy Establish recruitment
Human Research Protection Program. Investigator Manual
Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
Title: Review of Medical Devices Page: 1 of 5 Written by:
THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 031.1 Title: Review of Medical Devices Page: 1 of 5 Written by: Approved by: Laura W. Knight,
University of Rochester
University of Rochester Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form A. General Information Reason for Submission to ESCRO: New Project Response to Comments Reconsideration
The Presentation Will Begin At 12PM EST. Process Design: Problem Management Graham Furnis, Senior Consultant B Wyze Solutions
The Presentation Will Begin At 12PM EST Process Design: Problem Management Graham Furnis, Senior Consultant B Wyze Solutions Helping you to achieve breakthroughs in your organization! Templates Live Webinars
June 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB
June 15, 2016 Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA five consecutive audits
NIH Forms E Changes for Human Subject and/or Clinical Trial Applications Attached are the Forms E application pages with the most significant changes
NIH Forms E Changes for Human Subject and/or Clinical Trial Applications Attached are the Forms E application pages with the most significant changes (pages 11-16). Many of the new fields require a short
PARTNERS HUMAN RESEARCH COMMITTEE. Human Tissues: Brief Primer on Research Use and Requirement for Partners IRB Review
PARTNERS HUMAN RESEARCH COMMITTEE Human Tissues: Brief Primer on Research Use and Requirement for Partners IRB Review For the purposes of this Primer, tissue is defined as any biological specimen obtained
Disruptive Innovation and the Future of Medicine: Are We Prepared?
Disruptive Innovation and the Future of Medicine: Are We Prepared? Carolyn Compton, MD, PhD Professor of Life Sciences, Arizona State University Professor of Laboratory Medicine and Pathology, Mayo Clinic
To document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices.
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD COMPASSIONATE/TREATMENT USE OF MEDICAL DRUGS, BIOLOGICS AND DEVICES I. PURPOSE To document the review procedures for a submission
Institutional Review Board Compliance Elizabeth City State University
Institutional Review Board Compliance Elizabeth City State University Michelle Moore, MBA Research Compliance Officer/IRB Administrator Office of Sponsored Programs, Contracts & Grants 110 McLendon Hall
EuroNet- PHL- C2 trial set- up and trial monitoring
EuroNet- PHL- C2 trial set- up and trial monitoring Chris9ne Mauz- Körholz Department of Pediatrics Pediatric Hematology and Oncology UKGM, Justus- Liebig University of Gießen, Germany ScienCfic Secretary
POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011 Research investigating or evaluating drugs, biologics or devices must
Indiana University, Purdue University Indianapolis Institutional Biosafety Committee (IBC) Policy & Procedure Manual.
Indiana University, Purdue University Indianapolis Institutional Biosafety Committee (IBC) Policy & Procedure Manual Table of Contents A. Charge of the Committee (IBC)... 2 B. Membership.....2 C. Committee
T his presen ta o n can be do w n lo aded at
i T his presen ta o n can be do w n lo aded at w w w.o spe.o n.ca/ presen ta o n s 2 Outline of Presenta$on ² Data Sources for Today s Presenta,on ² Fundamental goal of CPD programs ² Stand alone CPD versus
METRICS THAT MATTER: ASSESSING WORKFLOW AND STAFFING
METRICS THAT MATTER: ASSESSING WORKFLOW AND STAFFING Michele Vaughan, BS, CCRP Research Strategy and Compliance Specialist Nationwide Children s Hospital, Columbus, OH Susan Sedwick, PhD, CRA, CSM Senior
Conducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
Strategic Planning. Copyright TREC
Strategic Planning TREC s Approach to Strategic Planning: A Five Step Process Plan to Plan Next Steps Pre- Planning The Plan Planning Session Step One Plan to Plan Key Outcome: Leaders are invested in
Administrative Policies VMC #638.1 and Procedures Manual
Administrative Policies VMC #638.1 and Procedures Manual January 14, 2013 TO: FROM: SUBJECT: REFERENCE: VMC Employees Paul E. Lorenz Chief Executive Officer, SCVMC Research Involving Human Subjects TJC,
Have you got it all? Creating a chemotherapy careplan formulary in an electronic medical record.
Poster Session HRT1317 Innovation Awards November 2013 Brisbane Have you got it all? Creating a chemotherapy careplan formulary in an electronic medical record. Presenter: Brett Ly Prince of Wales Hospital
4.1. Target Accrual Rate: The Target Accrual Goal divided by the Expected Duration (in days) of the trial.
POLICY #: COM-102 Page: 1 of 5 1. POLICY STATEMENT: The Scientific Review Committee (SRC) is responsible for monitoring the accrual and evaluating the scientific merit of each interventional clinical research
US Special Operations Command Human Research Protection Office
S- US Special Operations Command Human Research Protection Office Human Research Protocol Submission Form for Headquarters Level Administrative Review of Extramural* Research PURPOSE: All United States
Streamlining IRB Procedures for Expanded Access
Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs
13.0 Quality Improvement in the HRPP Program
13.0 Quality Improvement in the HRPP Program 13.1 Definitions Quality Improvement: A process initiated to develop/enhance a practice or procedure and to institutionalize the practice or procedure. Audit:
The Case for Collaboration: Corporate Participation in Collective Impact
The Case for Collaboration: Corporate Participation in Collective Impact 2014 Corporate Philanthropy Institute Boston Geneva San Francisco Seattle Washington For corporations, social issues in the enabling
THE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE
THE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE Dr John Lim Dr John Lim Chief Executive Officer Health Sciences Authority Singapore 13 October 2006 Ms Chan Cheng
HUMANITARIAN USE DEVICES 3/8/2016
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program HUMANITARIAN USE DEVICES 3/8/2016 It is the policy of the Duke University Health System Institutional Review Board (DUHS IRB) to review and
Title: IRB Purpose, Principles and Responsibilities Page: 1 of 5
THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 001.2 Title: IRB Purpose, Principles and Responsibilities Page: 1 of 5 Written by: Laura W. Knight,
TAB helps to organize, access and manage your critical documents and records by combining the best records management products and services with our
2016 Kurt Thies TAB helps to organize, access and manage your critical documents and records by combining the best records management products and services with our knowledge and experience. About TAB
Human Research Protection Program Education Plan
Human Research Protection Program Education Plan May 1, 2016 Human Research Protections Program e 1313 21 st Ave. South, Room 504 Oxford House, Nashville, Tennessee 37232-4315 e phone 615-322-2918 e fax
Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
Index of Frequently Asked Questions
Index of Frequently Asked Questions We hope that this frequently asked questions will orient you to basic policies and procedures for IRB review and approval. Feel free to call on us as you navigate the
Ad Hoc Report (Ad Hoc Report on Recommendation 1) Prepared for The Northwest Commission on Colleges and Universities
Ad Hoc Report (Ad Hoc Report on Recommendation 1) Prepared for The Northwest Commission on Colleges and Universities March 1, 2017 Table of Contents Introduction... 3 Update on Recommendation 1... 3 Upcoming
Multi Site Studies & Reliance Agreements (1)
Multi Site Studies & Reliance Agreements (1) If this study will be a 1) multi site study and/or 2) IRB review and approval by an external IRB is required (e.g., a hospital system IRB), and/or 3) the UNC
1. Purpose 2. Abbrevia1ons 3. TAS: Governance Ma:ers 4. TAS: HR Ma:ers 5. TAS: Opera1onal Ma:ers 6. TAS: Organiza1onal Structure 7.
1 16 August 2016 2 1. Purpose 2. Abbrevia1ons 3. TAS: Governance Ma:ers 4. TAS: HR Ma:ers 5. TAS: Opera1onal Ma:ers 6. TAS: Organiza1onal Structure 7. 2015/16 Audit Outcomes 3 DAC EE FS HoD IA JD Mancom
ISO Audit and Cer/fica/on of Trustworthy Digital Repositories, the Primary TDR Authorisa/on Body (PTAB) David GiareFa, Director APA
ISO Audit and Cer/fica/on of Trustworthy Digital Repositories, the Primary TDR Authorisa/on Body (PTAB) David GiareFa, Director APA Outline Role of Alliance for Permanent Access (APA) Overview of challenges
Division of Forestry
Division of Forestry Briefing for Wisconsin County Forest Associa5on September 29, 2017 Fred Souba, Jr. Division Administrator, Chief State Forester Mike Warnke Forestry Services Deputy Heather Berklund
Ethics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
System of Rice Intensification Research: a Review
System of Rice Intensification Research: a Review 1993-2013 Erika Styger, PhD SRI International Network and Resources Center (SRI-Rice) College of Agriculture and Life Sciences, Cornell University, Ithaca
PREP Course 24: Defining the Differences between FDA and OHRP regulations. Presented by: Hallie Kassan Dorean Flores Office of the IRB
PREP Course 24: Defining the Differences between FDA and OHRP regulations Presented by: Hallie Kassan Dorean Flores Office of the IRB CME Disclosure Statement The North Shore LIJ Health System adheres
Office for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
Advancing Women in Coaching through Mentorship
Advancing Women in Coaching through Mentorship Gretchen Kerr Vice- Dean, Faculty of Kinesiology and Physical Educa;on, University of Toronto The Landscape of Women in Leadership The Role of Mentorship
Investigator s Handbook
Page 96 CHAPTER 11 Investigational Drugs, Agents, Biologics, and Devices Investigational Drugs/Investigational Biologics (Test Articles) A new drug/agent or biologic that is used in a clinical investigation.
1.0 INTRODUCTION AND OVERVIEW
Table of Contents 1.0 INTRODUCTION AND OVERVIEW... 3 2.0 DEFINITIONS... 4 3.0 OVERSIGHT AND ORGANIZATION... 5 3.1 CLINICAL RESEARCH OVERSIGHT COMMITTEE (CROC)... 5 3.2 CLINICAL RESEARCH SUPPORT (CRS)...
Institutional Review - Protection of Human Subjects
The University of Toledo The University of Toledo Digital Repository Higher Learning Commission Office of the Provost Institutional Review - Protection of Human Subjects Research, Office of Follow this
11.0 FDA-Regulated Research
11.0 FDA-Regulated Research The HSC evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
Leading with a Quality Management System
Leading with a Quality Management System Research Administrative Services Office of Sponsored Projects Administration Janice Grace, MBA Manager-Research Operations Society of Research Administrators International
Module One: Produc.ve Management Methodology for Health Services (PMMHS) An Introduc.on Part 2
Module One: Produc.ve Management Methodology for Health Services (PMMHS) An Introduc.on Part 2 What is PMMHS? It is a methodology for the management of health services based on produc.on, efficiency, resources
Patrick White Senior Consultant Akvaplan-niva
Zone Management Patrick White Senior Consultant Akvaplan-niva Patrick White is a specialist in marine fish hatchery production and an expert on the environmental impacts of aquaculture. He has over 35
University of Utah Annual IRB Member Training Ann Johnson, PhD Associate Director Institutional Review Board
University of Utah Annual IRB Member Training 2016 Ann Johnson, PhD Associate Director Institutional Review Board Overview of NIH policy on the use of a Single IRB for multi site research (and other federal
1 Human Subjects Protection Training Manuel
1 Human Subjects Protection Training Manuel Human Subjects Protection: Training for Research Teams Brought to you by: Walter L. Calmbach MD MPH South Texas Ambulatory Research Network (STARNet) Dept. of
Tools, Templates, and Checklists for Streamlining IRB Protocol Review
Tools, Templates, and Checklists for Streamlining IRB Protocol Review Sharon Freitag, BSc Megan Kasimatis Singleton, JD, MBE, CIP May 5, 2016 Welcome! Nora Murphy Online Learning Coordinator PRIM&R 1 Content
Activities of the Korean Association of the Institutions Review Boards (KAIRB) in the year of Korea
Activities of the Korean Association of the Institutions Review Boards (KAIRB) in the year of 2002-2003 Korea October 18, 2003 Ock-Joo Kim, M.D., Ph.D. General Secretary of KAIRB (Seoul, Korea) I. Foundation
The European Spalla.on Source Business Opportuni.es. Luis Ortega Procurement Officer
The European Spalla.on Source Business Opportuni.es Luis Ortega Procurement Officer www.europeanspalla.onsource.se 29 April 2015 Topics Industry and ESS Business Opportuni.es ESS Procurement ESS In- kind
Human Subjects Protection: Training for Research Teams
Human Subjects Protection: Training for Research Teams Walter L. Calmbach MD MPH South Texas Ambulatory Research Network (STARNet) Dept. of Family & Community Medicine Univ. of Texas Health Science Center
Expanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
Advancing Clinical and Transla/onal Research with Informa/cs at the University of Kansas Medical Center
Advancing Clinical and Transla/onal Research with Informa/cs at the University of Kansas Medical Center Russ Waitman, PhD Director of Medical Informa1cs, Associate Professor, Department of Biosta1s1cs
Finding flexibility in the regulations. Mariette Marsh, MPA, CIP HCCA 2017 Baltimore, MD June 5, Disclosures
Finding flexibility in the regulations Mariette Marsh, MPA, CIP HCCA 2017 Baltimore, MD June 5, 2017 Disclosures Nothing to disclose and all opinions are my own 2 1 Agenda What is flexibility? Case study
Modelling Collec,ve Commons Problems: Future Scenarios for P2P Money
Modelling Collec,ve Commons Problems: Future Scenarios for P2P Money David Hales, University of Szeged, Hungary www.davidhales.com Diversity in Macro Conf. Feb 24-25 th 2014 University of Essex Who am